Welcome to our dedicated page for TransMedics Group SEC filings (Ticker: TMDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on TransMedics Group's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into TransMedics Group's regulatory disclosures and financial reporting.
TransMedics Group Inc reports a Schedule 13G filing by Vanguard Portfolio Management holding 1,949,420 shares of Common Stock, representing 5.68% of the class. The filing shows sole voting power for 29,885 shares and sole dispositive power over 1,949,420 shares as reported.
The filing names Vanguard Portfolio Management LLC and affiliated entities as the reporting persons and is signed on 04/29/2026.
TransMedics Group, Inc. presents its 2026 annual meeting proxy, highlighting strong 2025 performance and key governance items. The company reports $605.5 million in 2025 revenue, a 37% increase, driven by more than 5,100 U.S. OCS transplants and expanding use in liver and heart.
2025 was the first full year of positive cash flow, generating $152 million, and operating margin expanded to 18% from 8.5% in 2024. Management emphasizes a self-funding growth model, continued investment in its ENHANCE heart and DENOVO lung clinical programs, and development of its OCS Generation 3.0 platforms, including kidney.
Shareholders are asked to elect eight directors, approve an advisory “say on pay” vote for named executive officers, amend the 2019 Stock Incentive Plan, and ratify PricewaterhouseCoopers LLP as independent auditor. The proxy also details non-employee director pay, increased RSU-based equity awards, and executive pay structures that are heavily performance- and equity-based.
TransMedics Group Inc Schedule 13G/A reports that The Vanguard Group beneficially owns 0 shares of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 under SEC Release No. 34-39538, with certain Vanguard subsidiaries reporting ownership separately.
The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. It states Vanguard and its managed accounts retain rights to dividends or proceeds as described, while no single other person holds more than 5%.
TransMedics Group, Inc. officer Matthew S. Forsyth filed an initial Form 3 insider ownership report. This filing establishes him as a reporting officer of the company. The data provided shows no reported purchases, sales, option exercises, gifts, or other insider transactions at this time.
TransMedics Group, Inc. director Stephanie Lovell reported an open-market sale of common stock. On March 4, 2026, she sold 1,193 shares of TransMedics common stock at a price of $149.62 per share. After this transaction, she directly owned 2,866 shares of the company’s common stock.
TransMedics Group, Inc. director David Weill reported an option exercise and related share sale. On March 4, 2026, he exercised a stock option for 3,571 shares of common stock at $14.20 per share after the derivative security was fully vested. He then sold 3,571 shares of common stock in an open-market transaction at a price of $146.82 per share. After these transactions, he directly owned 12,134 shares of common stock and held 1,429 stock option shares.
TransMedics Group Chief Financial Officer Gerardo Hernandez reported both option exercises and share sales. On March 4, 2026, he exercised stock options that delivered 7,236 shares of common stock and, together with earlier activity, sold a total of 7,611 shares. Some of the shares were sold to satisfy tax withholding obligations tied to restricted stock unit vesting through a sell-to-cover transaction. Reported sale prices reflect a weighted average around $147.21 per share, based on multiple trades between $147.14 and $147.47. After these transactions, he directly held 14,689 TransMedics common shares.
TransMedics Group, Inc. insider Anil P. Ranganath reported an automatic sale of common stock tied to tax withholding on vested restricted stock units. On March 2, 2026, he sold 864 shares at $139.12 per share in an open-market transaction designated as a “sell to cover” for required tax obligations. After this sale, he directly held 13,091 common shares, so the transaction reflects tax-related share disposition rather than a discretionary reduction of his overall stake.
TransMedics Group executive Nicholas Corcoran reported share transactions linked to restricted stock unit vesting. On March 2, 2026, he executed an open-market sale of 2,966 shares of common stock at $139.12 per share, leaving him with 29,831 shares held directly.
Earlier, on January 23, 2026, 984 shares at $135.30 per share were disposed of to satisfy tax withholding obligations upon RSU vesting. Footnotes state both the issuer’s share withholding and the “sell to cover” sale were required to cover Corcoran’s tax liabilities tied to these equity awards.